However, in our study, knocking down CEP55 inhibited the progression of PAAD, so CEP55’s tumor-promoting effect may outweigh its effect of enhancing cuproptosis to inhibit PAAD. Here, CEP55 is linked to pancreatic adenocarcinoma.